



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Bagchi et al.

Appln. No.: 10/805,129

Conf. No.: 8914

Filed: March 19, 2004

Title: METHOD AND COMPOSITION FOR
DECREASING GHRELIN LEVELS

PATENT APPLICATION

Art Unit: 1614

Examiner: Weddington, Kevin E.

Atty. Docket No.: IHEL-01040US1

Customer No. 23910

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited in the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**, on the date shown below.

Mathew Otts (Signature)

Mathew Otts

Signature Date: 8/11/2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

Enclosed with this statement are the following:

- X Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.
- X Copies of cited U.S. patents and publications are not enclosed. However, copies of cited foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98(a)(2), as required.
- X If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. MPEP §609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement, 37 C.F.R. §1.98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).

— **PTA Statement under 37 C.F.R. §1.704(d).** Each item of information contained in the *Information Disclosure Statement* was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the *Information Disclosure Statement*.

This statement should be considered because:

X **37 C.F.R. §1.97(b).** This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:

- (1) It is being filed within three months of the filing date of an application other than a continued prosecution application under § 1.53(d);
-- OR --
- (2) It is being filed within 3 months of entry of a national stage;
-- OR --
- (3) It is being filed before the mailing date of the first Office Action on the merits,
-- OR --
- (4) It is being filed before the mailing date of the first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

X ***Fee Authorization.*** The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325. ***A duplicate copy of this authorization is enclosed.***

Respectfully submitted,


FLIESLER MEYER LLP

Date: August 11, 2005

By: 


Anthony G. Craig
Reg. No. 50,342

FLIESLER MEYER LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
Telephone: (415) 362-3800
Facsimile: (415) 362-2928
Customer No. 23910



Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

U.S. PATENTS							
Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
		4,923,855	May 8, 1990	Jensen			
		4,954,492	Sep. 4, 1990	Jensen			
		5,194,615	Mar. 16, 1993	Jensen			
		5,266,560	Nov 30, 1993	Furman et al.			
		5,480,657	Jan 2, 1996	Ann de Wees T. Allen			
		5,543,405	Aug. 6, 1996	Keown et al.			
		5,567,424	Oct. 22, 1996	Hastings			
		5,612,039	Mar 18, 1997	Policappelli et al.			
		5,626,849	May 6, 1997	Hastings et al.			
		5,716,976	Feb 10, 1998	Richard K. Bernstein			
		5,783,603	Jul 21, 1998	Majeed et al.			
		5,981,510	Nov. 9, 1999	Fujiwara et al.			
		6,034,125	Mar 7, 2000	Malcolm N. McLeod			
		6,048,846	Nov. 9, 1999	Cochran			
		6,100,251	Aug. 8, 2000	De la Harpe et al.			
		6,203,819	Mar. 20, 2001	Fine			
		6,207,714	Mar 27, 2001	Clouatre et al.			
		6,217,898	Apr 17, 2001	Claudio Cavazza			
		6,258,848	Jul 10, 2001	I. George Fantus			
		6,291,533	Sep. 18, 2001	Fleishner			
		6,352,713	Mar. 5, 2002	Kirschner et al.			
		6,383,482	May 7, 2002	Wayne F. Gorsek			
		6,399,089	Jun 4, 2002	Yegorova et al.			

Form PTO-1449 (Substitute) 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.			
	Filing/Issue Date March 19, 2004		Group Art Unit 1614	

		6,413,545	Jul. 2, 2002	Alviar et al.			
		6,541,026	Apr. 1, 2003	Siskind			
		6,579,866	Jun. 17, 2003	McCleary			
		6,589,566	Jul. 8, 2003	Ueda et al.			
		6,638,542	Oct. 28, 2003	Nieuwenhuizen et al.			

U.S. PATENT PUBLICATIONS

Examiner Initial		Patent Application Publication Number	Publication Date	Applicant
		2001/0031744	Oct. 18, 2001	Kosbab
		2003/0220329	Nov. 27, 2003	Surwit et al.
		2004/0157929	Aug 12, 2004	Ohia et al.
		2004/0186181	Sep 23, 2004	Bagchi et al.

PENDING U.S. PATENT APPLICATIONS

Examiner Initial		Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No
		60/554,653	Mar 19, 2004	Bagchi et al.	
		60/628,381	Nov 16, 2004	Bagchi et al.	
		09/463,024	Feb 15, 2002	G. Ganga Raju	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		WO 99/03464	28 Jan 1999	PCT			
		WO 00/12080	9 Mar 2000	PCT			

Examiner	Date Considered
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	

Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

		WO 02/078616	10 Oct 2002	PCT				
		EP 0 714 663	5 Jun 1996	EPO				
		WO 00/57729	5 Oct 2000	PCT				
		WO 00/48983	24 Aug 2000	PCT				

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)

	Calapai, Gioacchino et al., "Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis," <i>The Journal of Clinical Investigation</i> , Vol. 104 (7), pp. 975-982 (October 1999).
	Clouatre, Dallas, "Anti-Fat Nutrients," Pax Publishing, San Francisco, CA (1993).
	Goldberg, Burton, "Weight Loss - An alternative Medicine Definitive Guide," AlternativeMedicine.com Books, Tiburon, California.
	Kendall, Pat, "Beware of New Weight Loss Products," Food Science and Human Nutrition Specialist, Colorado State University Cooperative Extension (July 7, 1999).
	Halford, Jason et al., "Separate systems for serotonin and leptin in appetite control," <i>The Finnish Medical Society Duodecim, Ann Med</i> 2000; 32: 222-232.
	Heffernan, M.A., et al., "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment," <i>International Journal of Obesity</i> , Vol. 25, pp. 1442-1449 (2001).
	McCarty, M.F., "Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression - an adjuvant role for chromium picolinate?," <i>Medical Hypotheses</i> , 43: 247-252 (1994).
	Murray, Michael T., "Encyclopedia of Nutritional Supplements, The Essential Guide for Improving your Health Naturally," Prima Publishing, Random House, Inc., New York. Pp. 194-198 (1996).
	Ohia, Sunny E., et al., "Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX)," <i>Molecular and Cellular Biochemistry</i> , Vol. 238, pp. 89-103, 2002.
	Ohia, Sunny E., et al., "Effect of Hydroxycitric Acid on Serotonin Release from Isolated Rat Brain Cortex," <i>Research Communications in Molecular Pathology and Pharmacology</i> , Vol. 109, Nos. 3 & 4, March, April 2001, pp. 210-216.
	Palmeri, Denise, "Metabolife, Metabolite and Chitoslim: Safe Bets for Losing Weight?," ext.colostate.edu, May 2002 pp. 1-4
	Roy, Sashwati, et al., "Body Weight and Abdominal Fat Gene Expression Profile in Response to a Novel Hydroxycitric Acid-Based Dietary Supplement," <i>Gene Expression</i> , Vol. 11, pp.251-262, February 24, 2004.

Examiner	Date Considered
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN / _____, filed _____, 20____, relied on under 35 USC §120.	

Form PTO-1449 (Substitute) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number IHEAL-01040US1	Serial/Patent Number 10/805,129
	Applicant/Patent Owner Bagchi et al.	
	Filing/Issue Date March 19, 2004	Group Art Unit 1614

		Shara, Michael, et al., "Physico-chemical properties of a novel (--)hydroxycitric acid extract and its effect on body weight, selected organ weights, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry, and histopathological changes over a period of 90 days," <i>Molecular and Cellular Biochemistry</i> , Vol. 260, pp. 171-186, 3 October 2003.
		Tolbert, L.M. et al., "Serotonin induces mapk activation in primary cultures of cortical neurons," <i>Division of Molecular Psychiatry, Yale University, New Haven, CT, USA</i>
		Vergheze, James, "(-)-Hydroxycitrates - The usefulness of (-)-hydroxycitric acid as an obesity regulator is attracting more attention from the food & pharmaceutical industry. Can it be called an ingredient for functional foods?," <i>The World of Ingredients</i> .
		Yang, et al., "The synthesis animal experiments and preliminary clinical trial of chromium (III)-nicotinic acid-amino acids mixed ligand complexes," Database CAPLUS, Sch. Pharm, West China Univ. Med. Sci., (Chengdu, China), AN 1988:542370.
		AIM Metabolite (1999) AIM International, Inc.
		Chromium, http://www.supplementdirect.com/research/chromium.html , pp. 1-13
		Herbs and Weight Loss FAQ's; http://herbsforhealth.about.com/library , pp. 1-3
		Evaluating Natural Weight Loss Supplements, http://altmedicine.about.com/library/weekly ; pp. 1-8

<u>Examiner</u>	<u>Date Considered</u>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
*1 = Copy not submitted because it was submitted in prior application SN ____ / ____, filed ____, 20__, relied on under 35 USC §120.	
*2 = Copy not submitted because it was submitted in prior application SN ____ / ____, filed ____, 20__, relied on under 35 USC §120.	